We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

126 hedge funds and large institutions have $324M invested in Ventyx Biosciences in 2024 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 33 increasing their positions, 39 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

191% more capital invested

Capital invested by funds: $112M → $324M (+$213M)

23.08% more ownership

Funds ownership: 76.5%99.58% (+23%)

19% more call options, than puts

Call options by funds: $1.27M | Put options by funds: $1.07M

16% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 37

4% more funds holding

Funds holding: 121126 (+5)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

15% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 39

Holders
126
Holders Change
+5
Holders Change %
+4.13%
% of All Funds
1.82%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
43
Increased
33
Reduced
39
Closed
37
Calls
$1.27M
Puts
$1.07M
Net Calls
+$205K
Net Calls Change
+$2.73M
Name Holding Trade Value Shares
Change
Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$31.8M +$7.43M +1,624,939 +38%
BlackRock
2
BlackRock
New York
$20.6M -$308K -67,438 -2%
Vanguard Group
3
Vanguard Group
Pennsylvania
$20.4M -$167K -36,453 -1%
DM
4
Deerfield Management
New York
$19.5M +$16.2M +3,542,000 New
FCM
5
Farallon Capital Management
California
$17.4M +$14.5M +3,170,000 New
TCM
6
Tang Capital Management
California
$17.1M +$5.03M +1,100,000 +55%
CAM
7
Cormorant Asset Management
Massachusetts
$14.9M +$12.4M +2,710,000 New
Point72 Asset Management
8
Point72 Asset Management
Connecticut
$13.9M +$11.6M +2,531,002 New
SSA
9
Schonfeld Strategic Advisors
New York
$13M +$9.93M +2,171,200 +1,109%
Capital International Investors
10
Capital International Investors
California
$12.9M
RG
11
Redmile Group
California
$11.9M +$8.95M +1,956,923 +944%
O
12
OrbiMed
New York
$10.3M +$8.55M +1,870,456 New
Goldman Sachs
13
Goldman Sachs
New York
$9.26M +$1.47M +321,299 +24%
OCA
14
Octagon Capital Advisors
New York
$8.26M +$6.86M +1,501,114 New
Morgan Stanley
15
Morgan Stanley
New York
$7.34M -$11.4M -2,495,714 -65%
OM
16
Opaleye Management
Massachusetts
$7.07M +$663K +145,000 +13%
Adage Capital Partners
17
Adage Capital Partners
Massachusetts
$6.96M +$3.04M +665,050 +111%
PHP
18
Parkman Healthcare Partners
Connecticut
$6.64M +$5.52M +1,208,099 New
Geode Capital Management
19
Geode Capital Management
Massachusetts
$6.09M +$371K +81,191 +8%
SFM
20
Sphera Funds Management
Israel
$5.46M +$3.72M +812,749 +452%
JP Morgan Chase
21
JP Morgan Chase
New York
$5.24M +$3.86M +843,101 +764%
State Street
22
State Street
Massachusetts
$5.1M -$292K -63,834 -6%
TCM
23
TCG Crossover Management
California
$4.49M
FLAM
24
First Light Asset Management
Minnesota
$3.44M +$2.86M +624,842 New
IC
25
Ikarian Capital
Texas
$2.79M +$2.29M +501,733 +8,484%

VTYX Hedge Fund Activity: Q1 2024 in Review

126 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q1 2024, worth a combined $324M — up 191% from $112M a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new VTYX positions and 37 closed out — a net gain of 6 holders — while 33 added to existing stakes and 39 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $16.2M. The largest seller was Morgan Stanley, cutting an estimated $11.4M.

  • 126 institutional investors held Ventyx Biosciences (VTYX) as of Q1 2024, up from 121 in Q4 2023.
  • Funds reported $324M of Ventyx Biosciences stock for Q1 2024, up 191% quarter-over-quarter.
  • 43 funds opened new Ventyx Biosciences positions in Q1 2024 and 37 closed out, a net change of +6 holders.
  • The largest Ventyx Biosciences buyer in Q1 2024 was Deerfield Management, an estimated $16.2M added.
  • The largest Ventyx Biosciences seller in Q1 2024 was Morgan Stanley, an estimated $11.4M sold.

Based on aggregated 13F filings for Q1 2024.